For this position, the recruiting organisation is Vrije Universiteit Amsterdam (VUA) in Amsterdam, The Netherlands. The selected candidate will be employed within the POLARIS consortium, with academic supervision and project-specific expertise provided by the molecular pharmacology team at VUA.

Vrije Universiteit Amsterdam
Vrije Universiteit Amsterdam (VUA) is a research-intensive university with strong expertise in molecular pharmacology, drug discovery and cell signalling. Within POLARIS, VUA contributes knowledge in pharmacological target discovery and translational drug-development approaches, supporting the identification and validation of new therapeutic strategies for leukodystrophies.
This doctoral project focuses on molecular pharmacology and early-stage drug discovery for megalencephalic leukoencephalopathy with subcortical cysts (MLC), a rare genetic leukodystrophy for which no pharmacological treatment is currently available.
The project centres on GPRC5B, an orphan G protein-coupled receptor (GPCR) that has recently emerged as a promising therapeutic target in MLC. The candidate will investigate the pharmacological properties of this receptor and contribute to the development of novel modulators that may support future therapeutic strategies for leukodystrophies.
The work will combine receptor pharmacology, assay development and compound discovery. It will include the development and application of cell-based bioluminescent and fluorescent biosensor assays to study GPRC5B signalling in relevant cellular systems. The candidate will investigate receptor activation and signalling mechanisms, establish screening-compatible workflows, and apply these to identify and characterise candidate modulators.
A key part of the project will involve screening FDA-approved compounds for GPRC5B modulation and contributing to fragment-based drug discovery approaches. The candidate will help identify promising compounds for follow-up optimisation and downstream validation within the POLARIS network. Through this work, the project will contribute to building a structured pharmacological development pipeline for leukodystrophies.
The candidate will work at the interface of molecular pharmacology, rare disease biology and translational neuroscience. Planned secondments and network-wide training activities will provide additional interdisciplinary and intersectoral experience, including exposure to assay harmonisation, compound optimisation and in vivo characterisation of lead molecules.
The academic embedding will be at VU Amsterdam, with full participation in the broader POLARIS doctoral training programme.
Important, strict eligibility criteria according to MARIE SKLODOWSKA CURIE programs apply to applicants:
- You must not already hold a doctoral degree.
- At the time of the application deadline, you must have a Master’s degree and must not have resided or carried out your main activity (work, studies, etc.) in the Netherlands for more than 12 months in the three years prior to the contract start date.
- You will participate in the network-wide training programme of POLARIS, which includes (international) training activities and planned secondments with POLARIS partner organizations throughout the EU.
We are looking for a motivated candidate with a Master’s degree in pharmacology, molecular sciences, biomedical sciences, medicinal chemistry, life sciences or a related field. You have a strong interest in molecular pharmacology, GPCR biology, translational drug discovery and rare disease research.
Experience in molecular and cellular laboratory techniques, receptor pharmacology, cell culture, signalling assays or related experimental approaches would be considered an advantage. Familiarity with cell-based assay development, fluorescence- or bioluminescence-based readouts, compound screening, or molecular biology techniques would be valuable. Experience with drug discovery approaches or fluorescence microscopy would also be beneficial.
You work accurately and reproducibly, have strong analytical and organisational skills, and are able to collaborate effectively in an interdisciplinary and international research environment.
- A contract for 12 months, with the intention to extend for a total of 3 years;
- Salary, mobility allowance and benefits according to the applicable MSCA Doctoral Network and host-organisation rules;
- Embedding in the international POLARIS doctoral training network;
- Access to network-wide training activities, secondments and transferable-skills development;
- A challenging and translational research project at the interface of in vivo neuroscience, rare disease biology and preclinical therapy development;
- An open and supportive team culture with opportunities for scientific and professional development.
Applications for the doctoral positions have now closed. The selection process is currently ongoing, and applications are being reviewed by the recruiting institutions.
POLARIS is now moving into the next phase of its doctoral programme, which will bring together a new cohort of researchers working across disciplines and sectors to advance translational research in leukodystrophies.














